Phyto Partners is a venture capital firm specializing in investments within the cannabis and neurowellness sectors. Established in 2015, the firm has deployed capital into over 30 portfolio companies, focusing on ancillary businesses that provide critical solutions to licensed operators. Their areas of investment include advertising technology, agriculture technology, biotechnology, brand building, cannabis delivery services, data, education, hemp/CBD, intellectual property, medical dosing technology, and software (SaaS).

Phyto Partners aims to be more than just a financial sponsor by offering strategic support, business development assistance, and leveraging their extensive industry network to introduce portfolio companies to potential customers, investors, and M&A targets. The firm has been recognized as a Top Cannabis Investment Fund by Forbes and Business Insider. In 2018, they launched Phyto II, a $100 million fund targeting privately held companies in the cannabis industry.

In 2020, they introduced Phyto III, a $50 million fund focusing on early and later-stage companies addressing critical industry challenges. In 2022, Phyto Partners expanded its focus to neurowellness and brain health with the launch of Phyto IV, a fund dedicated to businesses operating in and around these sectors, including the use of psychedelic compounds for mental well-being.